单克隆丙种球蛋白病筛查的临床与心理结局:人群筛查及后续随机随访试验
在冰岛开展全国性单克隆丙种球蛋白病筛查(75,422人参与),3,541例MGUS患者随机分为不通知组、指南随访组和强化随访组。中位随访4.5年,筛查使冒烟型多发性骨髓瘤检出率增加27倍,但活动性恶性肿瘤发生率无差异;干预组活动性MM及相关恶性肿瘤诊断提前1年,诊断时症状表现和住院更少,且MGUS通知未带来不良心理结局。
要点
- 人群MGUS筛查使冒烟型MM检出率增加27倍,但未改变活动性恶性肿瘤总体发生率。
- 干预组活动性MM及相关恶性肿瘤诊断提前1年,诊断时症状和住院更少。
- MGUS通知未导致可检测的不良心理结局,支持筛查无害性。
核心结论
- 人群筛查可促进MM早期检出并扩大早期干预可及性,且未发现可检测的心理伤害。
- 需更长期随访以确定对生存和成本效果的影响。
研究设计与样本
- 冰岛全国性筛查研究及后续随机试验(Iceland Screens, Treats, or Prevents Multiple Myeloma;NCT03327597)。
- 共筛查75,422人(受邀者的53%),3,541例MGUS患者随机分配至不通知组(arm 1)、指南随访组(arm 2)或强化随访组(arm 3)。
- 比较对照组(arm 1)与干预组(arm 2和3)的疾病进展、症状负担和心理健康。
主要发现
- 中位随访4.5年,筛查使冒烟型MM检出率增加27倍(8.6% vs 0.3%;HR 27.46 [95% CI 10.21 to 73.86];P < .001)。
- 活动性恶性肿瘤发生率无差异。
- 干预组活动性MM及相关恶性肿瘤诊断提前1年,诊断时症状表现和住院更少。
- MGUS通知与不良心理结局无关。
临床怎么用
- 筛查有助于更早发现MM及相关恶性肿瘤,使诊断时症状和住院减少。
- 对MGUS患者进行通知和随访未显示心理伤害,可考虑纳入筛查与随访策略。
局限性
- 需更长随访以评估筛查对生存和成本效果的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) and related malignancies develop from an asymptomatic precursor condition, monoclonal gammopathy of undetermined significance (MGUS), detectable via blood testing. The benefits and harms of population-based MGUS screening remain uncertain. We conducted a nationwide screening study for monoclonal gammopathies and a randomized trial of follow-up strategies in Iceland (Iceland Screens, Treats, or Prevents Multiple Myeloma; ClinicalTrials.gov identifier: NCT03327597). In total, 75,422 (53% of those invited) were screened and those with MGUS (n = 3,541) were randomly assigned to no notification (arm 1), guideline-based follow-up (arm 2), or intensified follow-up (arm 3). Progression, symptom burden, and psychological well-being were compared between the control arm (arm 1) and intervention arms (arms 2 and 3). After a median follow-up of 4.5 years, screening led to a 27-fold increase in the detection of smoldering MM (8.6% v 0.3%; hazard ratio, 27.46 [95% CI, 10.21 to 73.86]; P < .001), but active malignancy rates did not differ. Active MM and related malignancy were diagnosed 1 year earlier in the intervention arms with fewer symptomatic presentations and hospitalizations at diagnosis. MGUS notification was not associated with adverse psychological outcomes. These findings demonstrate that population-based screening facilitates earlier detection of MM and expands access to early intervention without detectable psychological harm. Longer follow-up is required to determine the effects on survival and cost-effectiveness.
引用
- Rögnvaldsson S, Thorsteinsdóttir S, Eythorsson E, et al. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up. J Clin Oncol. 2026. PMID: 42447419. doi:10.1200/JCO-25-02771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。